See the DrugPatentWatch profile for Mektovi
What is Mektovi?
Mektovi is a prescription medicine that contains the active ingredient binimetinib. It is used to treat certain cancers with specific genetic features. The product is intended for patients whose tumors carry a BRAF mutation, and it is typically used in combination with another drug (commonly encorafenib), based on the cancer type and mutation status.
What cancers does Mektovi treat?
Mektovi is used for cancers where testing shows a relevant BRAF mutation, and when the treatment approach matches the approved combination and indication. Its use depends on:
- the type of cancer (for example, melanoma versus other BRAF-mutant cancers), and
- the specific BRAF mutation found by a companion diagnostic test.
How is Mektovi usually taken (and what to expect)?
Mektovi is taken by mouth. The exact dosing schedule and instructions depend on:
- the approved regimen for the specific cancer type, and
- how it’s combined with the partner medicine (often encorafenib).
If you tell me the condition you mean (for example, “BRAF V600-mutant melanoma”), I can help map the typical dosing and combination used for that scenario based on the information available.
What are common side effects people report?
Side effects vary by patient and by combination regimen. With binimetinib-based therapy, commonly discussed effects include issues related to:
- the skin,
- the gastrointestinal system (such as nausea or diarrhea),
- fatigue, and
- lab or organ-related changes (for example, changes involving the heart or eyes can be monitored during treatment).
Why is tumor BRAF testing important for Mektovi?
Mektovi’s benefit depends on the tumor having the right BRAF mutation. That’s why clinicians generally require:
- a molecular test (companion diagnostic or approved testing method), and
- confirmation that the patient meets the indication for the specific combination.
Can Mektovi be used alone?
In many approved regimens, binimetinib is used with encorafenib rather than by itself. Whether monotherapy is allowed depends on the specific indication and regulatory approval for that cancer type.
What happens if you miss a dose?
General oral targeted-therapy guidance is usually that patients should follow the prescribing information for missed doses (often based on how close the next dose is). If you share your regimen (and strength/dosing schedule), I can help interpret the typical “missed dose” instructions.
Who makes Mektovi and is it still under patent/exclusivity?
This depends on the product’s regulatory history by country and whether any biosimilar/alternative formulations exist. If you share your country (US, UK, EU, etc.), I can tailor the answer to the local status.
What do you want to know about Mektovi specifically?
People search Mektovi for different reasons. Tell me which one applies:
- “What is Mektovi used for?”
- “Mektovi + encorafenib dosing for my cancer type”
- “Side effects and when to call the doctor”
- “Is it approved in my country?”
- “Drug interactions and monitoring tests”